TransMedics

The company's business is centered on its Organ Care System (OCS), a portable platform that keeps donor organs alive and functioning in a near-physiological state outside the body. This technology perfuses the organ with warm, oxygenated, and nutrient-enriched blood, allowing for continuous monitoring and assessment of its viability, a significant departure from static cold storage on ice. The OCS is the only platform with FDA approval for preserving and assessing donor hearts, lungs, and livers in the United States. Key regulatory milestones include FDA pre-market approval for the OCS Lung in 2018, the OCS Heart for donors after brain death (DBD) in 2021, and the OCS Liver in 2021, with an expanded indication for DCD hearts in 2022. TransMedics went public on May 2, 2019, trading on the Nasdaq under the ticker TMDX, which provided capital for growth and commercial expansion.

TransMedics generates revenue through a model that analysts describe as a 'razor-and-blade' strategy. It involves the direct sale of the OCS console to transplant centers and hospitals, followed by recurring revenue from the sale of single-use proprietary disposable sets required for each transplant procedure. The company has expanded its business model to include a comprehensive service offering called the National OCS Program (NOP). The NOP provides an end-to-end solution, including trained organ procurement surgeons, clinical specialists, logistics, and transportation, leveraging a dedicated fleet of aircraft following the acquisition of Summit Aviation. This vertical integration streamlines the complex logistics of organ retrieval, enabling transplant centers to increase their geographic reach for donor organs and grow transplant volumes. Service revenue from the NOP has become a significant and growing portion of the company's overall income.